Drug intelligence / Profile preview

VDA-007

Development stage: Preclinical
Lead developer: viDA Therapeutics
Modality: Small Molecules, Therapeutic Enzymes → Recombinant Proteins and Enzymes

Overview

VDA-007 is a preclinical-stage drug candidate developed by viDA Therapeutics. It acts as a modulator of granzyme K (GZMK), an enzyme implicated in immune system diseases. The drug is being investigated for its potential to treat disorders related to immune system dysfunction by targeting and modulating the activity of GZMK, which plays a role in inflammation and immune responses[1].

Targets

GZMK (Granzyme K)

Beyond the preview

Go deeper on VDA-007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VDA-007.

Explore the full profile